臺灣博碩士論文加值系統

全球藥品市場規模龐大且逐年增加，加上近年人們對於藥品安全及醫療效果要求提高，藥品審核程序增加，使得藥品研發過程對製藥公司益顯重要，因此，本研究將探討藥品研發過程中所造成的股價波動，了解股價否有異常報酬率的情形。本研究探討:（一）檢視Pfizer藥廠在藥品研發過程中發生的「事件」是否會造成股票變動；（二） 檢視Pfizer藥廠在研發過程中發生的「事件」是否與其競爭者有連動關係；（三）以Pfizer藥廠在藥品研發過程中發生的同一「事件」，官方資料庫事件公開日與大眾媒體的事件報導日，比較兩者對Pfizer藥廠股價的表現。本文將資料來源分為兩大類，運用美國食品藥品監督管理局橘皮書（FDA orange book）、美國臨床資料庫以及Web of Science作為官方資料來源，華爾街日報報導作為大眾媒體資料來源，蒐集其創立日期至2018年12月31之公開日期，透過使用事件研究法探討專利核准與到期日、臨床試驗訊息發布日、論文發表日、FDA批准新藥核准日以及競爭者對藥廠的訴訟判決日之股價異常報酬率之波動。研究結果發現，Pfizer藥廠的股價在受到大眾媒體報導前，會受到藥品核准事件、訴訟勝訴事件與訴訟和解事件的影響，且沒有發現競爭者的股價與Pfizer藥廠有連動關係，此外，針對同一事件，官方資料庫與大眾媒體報導時間差不一致。本文之研究結果可幫助投資人進行相關議題之股票的投資參考，並協助藥廠進行藥品研發歷程中的資源分配。

The circulation of money of the global medicine market is large-scale and growing year by year. In addition, the requirement for high quality medicines and the procedure for verifying medicines’ quality becoming complicated in recent years make medicinal research and development more important for pharmaceutical companies.

In order to find out the fluctuations of shares during the medicinal research and development process, this study adopts an event study methodology to capture the abnormal return resulted from the specific announcement of event. In this study, I choose Pfizer as my research subject because Pfizer is the pharmaceutical company which has the best sales performance in 2018.

This study aims to: 1) examine whether the events happened during the medicinal research and development process would affect Pfizer’s shares or not; 2) examine whether the events happened during the medicinal research and development process correlate to other pharmaceutical companies or not; 3) compare the fluctuations caused by the event dates written in the official databases and in the mass media.

The events which are chosen to be the independent variables in the medicinal development processes include the patent application dates, the patent expiration dates, the clinical trial announcement dates, the article publication dates, the FDA drug license approval dates and the trial judgment dates for the lawsuits with competitors. The events data are collected from the official databases which include the FDA Orange Book, clinicaltrials.gov and Web of Science, and from the mass media which include the Wall Street Journal. The data’s time range is from the date when the data sources established to December 31, 2018.This study shows, the patent application dates and the trial judgment dates for the lawsuits with competitors would affect Pfizer’s shares before the mass media report, but other competitor’s shares would not correlate with Pfizer’s. Besides, the Wall Street Journal and other data sources have time gap while reporting the same events. This study could be an indicator to help investors to invest in global stock market and to help pharmaceutical companies to draw up a medicinal research and development strategy and to make a good resource allocation in the working process.

口試委員會審定書 i
中文摘要 ii
英文摘要 iii
第一章 緒論 1
第一節、研究背景 1
第二節、研究動機 2
第三節、研究目的 3
第二章 文獻探討 5
第一節、藥品研發歷程 5
第二節、影響股價的事件類型 11
第三節、事件研究法分析股價波動 15
第三章 研究方法 20
第一節、資料來源與樣本 20
第二節、藥品研發歷程事件 33
第三節、事件研究分析方法 37
第四章 實證結果 39
第一節、專利核准日與專利到期日 39
第二節、臨床試驗日 44
第三節、論文發表日 47
第四節、藥品核准日與藥品到期日 48
第五節、訴訟判決日 55
第六節、綜合討論 59
第五章 結論與建議 66
第一節、結論 66
第二節、建議 67
第三節、研究限制與未來建議 68
參考文獻 69

台大醫院衛教與諮詢專區（2019）。臨床試驗的分期。檢自:http://t.cn/EahVNkm
沈中華、李建然（2000）。事件研究法: 財務與會計實證研究必備: 華泰文化.
林哲鵬、郭怡萍，2007，「競爭策略下新產品宣告對股價的影響：就台灣資訊電子產業公司之檢視」，科技管理學刊，12(1)：1-28
翁鶯娟. (2002). 購併宣告對產業內競爭對手公司股價影響 之研究—以台灣上市公司為例. 成功大學企業管理學系碩士在職專班學位論文, 1-52.
陳光政、紀信義（2017）。製藥公司藥品許可證、研發與分析師盈餘預測關聯性之研究。中山管理評論, 25（2）, 291-336. doi:10.6160/2017.06.01
陸冠瑋. (2000). 美國上市公司策略聯盟宣告對產業競爭者影響之研究. 元智大學管理研究所學位論文, 1-0.
劉適寧（2018）。TrendForce：2018 年全球藥品市場規模預估為 1.2 兆美元，年增率為 3.8%。取自 https://press.trendforce.com.tw/press/20181224-3852.html
Abud, M. J., Hall, B., & Helmers, C. (2015). An empirical analysis of primary and secondary pharmaceutical patents in Chile. PloS one, 10(4), e0124257.
Angell, M. (2005). The truth about the drug companies: How they deceive us and what to do about it: Random House Incorporated.
Arundel, A., & Kabla, I. (1998). What percentage of innovations are patented? Empirical estimates for European firms. Research Policy, 27(2), 127-141.
Ball, R., & Brown, P. (1968). An empirical evaluation of accounting income numbers. Journal of accounting research, 159-178.
Ball, R., & Brown, P. (2019). Ball and Brown(1968) after fifty years. Pacific-Basin Finance Journal, 53, 410-431.
Borah, A., & Tellis, G. J. (2014). Make, buy, or ally? Choice of and payoff from announcements of alternate strategies for innovations. Marketing Science, 33(1), 114-133.
Brenner, M. (1979). The sensitivity of the efficient market hypothesis to alternative specifications of the market model. The Journal of Finance, 34(4), 915-929.
Bulow, J. I., Geanakoplos, J. D., & Klemperer, P. D. (1985). Multimarket oligopoly: Strategic substitutes and complements. Journal of Political economy, 93(3), 488-511.
Chang, K.-C., Chen, D.-Z., & Huang, M.-H. (2012). The relationships between the patent performance and corporation performance. Journal of Informetrics, 6(1), 131-139.
Chen, Y., Ganesan, S., & Liu, Y. (2009). Does a firm''s product-recall strategy affect its financial value? An examination of strategic alternatives during product-harm crises. Journal of Marketing, 73(6), 214-226.
Chen, Y., Liu, Y., & Zhang, J. (2012). When do third-party product reviews affect firm value and what can firms do? The case of media critics and professional movie reviews. Journal of Marketing, 76(2), 116-134.
Chong, C. R., & Sullivan Jr, D. J. (2007). New uses for old drugs. Nature, 448(7154), 645.
Desai, J. R., Bowen, E. A., Danielson, M. M., Allam, R. R., & Cantor, M. N. (2013). Creation and implementation of a historical controls database from randomized clinical trials. Journal of the American Medical Informatics Association, 20(e1), e162-e168.
Douglas W. House (2019).Vivus up 6% premarket on published Qsymia CV data.Retrieved from https://seekingalpha.com/news/3422649-vivus-6-percent-premarket-published-qsymia-cv-data
Fama, E. F. (1965). The behavior of stock-market prices. The journal of Business, 38(1), 34-105.
Fama, E. F., Fisher, L., Jensen, M. C., & Roll, R. (1969). The adjustment of stock prices to new information. International economic review, 10(1), 1-21.
Filson, D., & Oweis, A. (2010). The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry. Journal of health economics, 29(4), 575-584.
Gambardella, A. (1995). Science and innovation: The US pharmaceutical industry during the 1980s: Cambridge University Press.
Gielens, K., Van de Gucht, L. M., Steenkamp, J.-B. E., & Dekimpe, M. G. (2008). Dancing with a giant: The effect of Wal-Mart''s entry into the United Kingdom on the performance of European retailers. Journal of Marketing Research, 45(5), 519-534.
Henderson Jr, G. V. (1990). Problems and solutions in conducting event studies. Journal of Risk and Insurance, 282-306.
Hwang, T. J. (2013). Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies. PloS one, 8(8), e71966.
Jiang, J., Wang, I. Y., & Xie, Y. (2015). Does it matter who serves on the Financial Accounting Standards Board? Bob Herz’s resignation and fair value accounting for loans. Review of Accounting Studies, 20(1), 371-394.
Kiran, S., & Kulkarni, M. (2018). Secondary patents in the pharmaceutical industry: missing the wood for the trees? Expert opinion on therapeutic patents, 28(3), 241-250.
Ledford, H. (2011). Blockbuster drug bows out: pharmaceutical industry anxiously struggles to retool as Lipitor patent expires. Nature, 480(7375), 16-18.
Lee, D. S., & Mas, A. (2012). Long-run impacts of unions on firms: New evidence from financial markets, 1961–1999. The Quarterly Journal of Economics, 127(1), 333-378.
Levin, R. C., Klevorick, A. K., Nelson, R. R., Winter, S. G., Gilbert, R., & Griliches, Z. (1987). Appropriating the returns from industrial research and development. Brookings papers on economic activity, 1987(3), 783-831.
Levinthal, D. A., & March, J. G. (1993). The myopia of learning. Strategic Management Journal, 14(S2), 95-112.
Lichtenberg, F. R. (2005). The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982–2001. International journal of health care finance and economics, 5(1), 47-73.
Liu, Q. (2006). How good is good news? Technology depth, book-to-market ratio, and innovative events. Journal of Accounting, Auditing & Finance, 21(3), 293-321.
Mann, B. J. S., & Babbar, S. (2017). Stock Price Reaction Around New Product Announcements: An Event Study. IUP Journal of Management Research, 16(3).
Mc Namara, P., & Baden-Fuller, C. (2007). Shareholder returns and the exploration–exploitation dilemma: R&D announcements by biotechnology firms. Research Policy, 36(4), 548-565.
Michael Christel (2018)。Pharm Exec''s Top 50 Companies 2018。Retrieved from http://www.pharmexec.com/pharm-execs-top-50-companies-2018
Miller, J. M., Collman, B. M., Greene, L. R., Grant, D. J., & Blackburn, A. C. (2005). Identifying the stable polymorph early in the drug discovery–development process. Pharmaceutical development and technology, 10(2), 291-297.
Monique Ellis. (2019). Who are the top 10 pharmaceutical companies in the world? Retrieved from https://www.proclinical.com/blogs/2019-3/the-top-10-pharmaceutical-companies-in-the-world-2019
Motohashi, K. (2007). The changing autarky pharmaceutical R&D process: causes and consequences of growing R&D collaboration in Japanese firms. International Journal of Technology Management, 39(1), 33-48.
Narayanan, V., Pinches, G. E., Kelm, K. M., & Lander, D. M. (2000). The influence of voluntarily disclosed qualitative information. Strategic Management Journal, 21(7), 707-722.
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006). How many drug targets are there? Nature reviews Drug discovery, 5(12), 993.
Pan, L., McNamara, G., Lee, J. J., Haleblian, J., & Devers, C. E. (2018). Give it to us straight(most of the time): Top managers’ use of concrete language and its effect on investor reactions. Strategic Management Journal, 39(8), 2204-2225.
Panattoni, L. E. (2011). The effect of Paragraph IV decisions and generic entry before patentexpiration on brand pharmaceutical firms. Journal of health economics, 30(1), 126-145.
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry''s grand challenge. Nature reviews Drug discovery, 9(3), 203.
Pérez-Rodríguez, J. V., & Valcarcel, B. G. (2012). Do product innovation and news about the R&D process produce large price changes and overreaction? The case of pharmaceutical stock prices. Applied Economics, 44(17), 2217-2229.
Robbins, S. P. (1990). Organization Theory: Structures, Designs, And Applications, 3/e: Pearson Education India.
Schmid, E. F., & Smith, D. A. (2005). Keynote review: is declining innovation in the pharmaceutical industry a myth? Drug discovery today, 10(15), 1031-1039.
Sharma, A., & Lacey, N. (2004). Linking product development outcomes to market valuation of the firm: The case of the US pharmaceutical industry. Journal of Product Innovation Management, 21(5), 297-308.
Slovin, M. B., Sushka, M. E., & Bendeck, Y. M. (1991). The intra‐industry effects of going‐private transactions. The Journal of Finance, 46(4), 1537-1550.
Sternitzke, C. (2010). Knowledge sources, patent protection, and commercialization of pharmaceutical innovations. Research Policy, 39(6), 810-821.
Subramani, M., & Walden, E. (2001). The impact of e-commerce announcements on the market value of firms. Information Systems Research, 12(2), 135-154.
Swaminathan, V., & Moorman, C. (2009). Marketing alliances, firm networks, and firm value creation. Journal of Marketing, 73(5), 52-69.
Swaminathan, V., Murshed, F., & Hulland, J. (2008). Value creation following merger and acquisition announcements: the role of strategic emphasis alignment. Journal of Marketing Research, 45(1), 33-47.
USA Food and Drug Administration. (2018a). Step 3: Clinical Research. Retrieved from :https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm
USA Food and Drug Administration. (2018b). Frequently Asked Questions on Patents and Exclusivity. Retrieved from : https://www.fda.gov/drugs/developmentapprovalprocess/ucm079031.htm
USA Food and Drug Administration. (2015). FDA''s Drug Review Process: Continued。Retrieved from: https://www.fda.gov/Drugs/ResourcesForYou/Consumers /ucm289601.htm
Wiles, M. A., Morgan, N. A., & Rego, L. L. (2012). The effect of brand acquisition and disposal on stock returns. Journal of Marketing, 76(1), 38-58.
Xiong, G., & Bharadwaj, S. (2013). Asymmetric roles of advertising and marketing capability in financial returns to news: Turning bad into good and good into great. Journal of Marketing Research, 50(6), 706-724.
Xu, B. (2006). R&D Progress, stock price volatility, and post-announcement drift: An empirical investigation into biotech firms. Review of Quantitative Finance and Accounting, 26(4), 391-408.
Yang, H., & Lee, H. (2018). Long-term collaboration network based on ClinicalTrials. gov database in the pharmaceutical industry. Sustainability, 10(2), 322.
Yang, S.-B., Lim, J.-H., Oh, W., Animesh, A., & Pinsonneault, A. (2012). Research note—Using real options to investigate the market value of virtual world businesses. Information Systems Research, 23(3-part-2), 1011-1029.